| Literature DB >> 26159751 |
Austen J J Worth1, Adrian J Thrasher.
Abstract
Wiskott-Aldrich syndrome is a life-threatening primary immunodeficiency associated with a bleeding tendency, eczema and a high incidence of autoimmunity and malignancy. Stem cell transplantation offers the opportunity of cure for all these complications, and over the past 35 years there has been a remarkable improvement in survival following this treatment. Here, we review advances in management of clinical complications pre- and post-transplant, as well as discuss the morbidity Wiskott-Aldrich syndrome patients experience following treatment. For patients with a poorly matched stem cell donor, recent gene therapy trials demonstrate encouraging results and the potential of low-toxicity therapy for all patients.Entities:
Keywords: Wiskott Aldrich syndrome; Wiskott Aldrich syndrome protein; X-linked thrombocytopenia; allogeneic hematopoietic stem cell transplantation; autoimmunity; gene therapy; primary immunodeficiency; thrombocytopenia
Mesh:
Substances:
Year: 2015 PMID: 26159751 DOI: 10.1586/1744666X.2015.1062366
Source DB: PubMed Journal: Expert Rev Clin Immunol ISSN: 1744-666X Impact factor: 4.473